In this issue of Cancer Discovery , Horwitz and colleagues identifi ed a subtype of hepatocelluar carcinoma (HCC) bearing VEGFA genomic amplifi cation that is particularly sensitive to VEGFA inhibition and is also more sensitive to sorafenib treatment. Taken conjointly, these data suggest that VEGFA genomic amplifi cation can be used as a biomarker for personalized treatment of HCC with sorafenib. Cancer Discov; 4(6); 640-1.
Liver cancer has moved up the ranks from the third most common cause of cancer-related death to the second, with 0.8 million new patients annually and a 9.1% death rate worldwide, according to the recently released World Cancer Report 2014 ( 1 ) . In North America, liver cancer has also shown increasing prevalence ( 2 ) . Primary liver cancer includes hepatocelluar carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), with HCC responsible for 85% of cases worldwide, making it the major type of primary liver cancer ( 3 ) . HCC treatment implementations vary and depend on cancer stages. For early-stage HCCs, surgical resection is the best choice with an overall survival rate as high as 90% with well-selected patients. However, for advanced-stage disease, options in hand are extremely limited, with sorafenib the only systemic medicine available.
Sorafenib, a small molecule, targets multiple kinases, including VEGFR, PDGFRβ, RAF1, and BRAF. Both in vivo and in vitro experiments have demonstrated its abilities to inhibit tumor-cell proliferation and tumor angiogenesis and to promote apoptosis ( 4 ) . In 2005, the FDA approved sorafenib for treatment of advanced renal cell carcinoma, and 2 years later, it was approved for treatment of advancedstage HCC. Unfortunately, sorafenib's therapeutic effects fell short of expectations. Compared with the placebo group, the experimental group exhibited only 2.8 months longer median overall survival. In addition, severe side effects, including weight loss, hypophosphatemia, diarrhea, and hand-foot skin reaction, appeared more frequently in the sorafenib group ( 5 ) . One possible reason for the mild effect of sorafenib is that some patients were not sensitive to sorafenib treatment, which implies that a more stringent patient selection procedure along with specifi c predictive biomarkers is urgently needed to benefi t treatment. Indeed, some investigations have already been performed to this end. Although low-baseline hepatocyte growth factor (HGF ) and high-baseline soluble c-KIT concentration separately showed a favorable tendency to sorafenib treatment, neither of them approached statistical signifi cance ( 6 ) . Because sorafenib is used worldwide as standard care for patients with advanced-stage HCC and is the only systemic medicine to show benefi cial effect, more effort is warranted to optimize patient selection. In this issue of Cancer Discovery , a collaborative report from the laboratories of Ben-Neriah and Pikarsky (7) identifi ed a subtype of HCCs bearing VEGFA genomic amplifi cation that was particularly sensitive to VEGFA inhibition. Moreover, patients with HCC with similar amplifi cation respond favorably to sorafenib treatment.
Infl ammation and microenvironmental changes are hallmarks of liver cancer. In HCCs, some factors affecting these two hallmarks may be amplifi ed or deleted. To search for these factors, the authors applied array comparative genomic hybridization (aCGH) to HCC samples isolated from Mdr2 −/− mice, an infl ammation-driven HCC mouse model. They found that Chr17qB3 is present among these amplifi ed regions. VEGFA , encoding an important cytokine regulating the microenvironment, is located in this region. More importantly, Horwitz and colleagues ( 7 ) found that VEGFA amplifi cations also occurred in 11% of human HCC samples. Unsurprisingly, elevated VEGFA protein levels were detected in both tumor extracts and serum samples. Subsequent experiments established that HCCs harboring genomic VEGFA amplifi cation were indeed different from those without the amplifi cation. These tumors exhibited higher proliferation index, vessel density, and macrophage content but a lower incidence of fi brosis. All these data indicated that the microenvironment of these tumors indeed changed in correlation with VEGFA amplifi cation.
Because VEGFA cannot directly activate hepatocytes effi ciently ( 8 ) , the authors proposed a very interesting macrophage-tumor cell cross-talk model. In this model, VEGFA, secreted by tumor cells, stimulates macrophages to produce more HGF, which acts back on tumor cells and stimulates their proliferation. The data they presented strongly supported this hypothesis. They observed that tumor cells are the major cell type expressing VEGFA, whereas HGF is mainly expressed by macrophages. Aligning with these fi ndings, they found that the expression levels of VEGFRs and coreceptors were higher in macrophages, whereas more HGF receptors were expressed in hepatocytes. Interestingly, VEGFA can increase cellular proliferation in vivo but not in vitro , which further proved that VEGFA was not directly affecting tumor cells but rather communication with macrophages.
As VEGFR is one of the targets of sorafenib, the authors tested whether this drug had a selective advantage in mouse tumors with VEGFA genomic amplifi cation. Although they administered sorafenib to mice only for a short period of time, the results were inspiring. Only HCC with VEGFA genomic amplifi cation responded to sorafenib treatment and showed decreased proliferation. This conclusion was confi rmed by a Hep3B xenograft experiment. Moreover, the authors extended their investigation to human HCC patient samples. A retrospective study of a human cohort showed that a dramatic improvement was observed in the VEGFAamplifi ed group compared with the nonamplifi ed group in sorafenib-treated patients. All these data suggest that genomic VEGFA amplifi cation could be a biomarker that predicts HCC patient response to sorafenib treatment.
The fi ndings of Horwitz and colleagues ( 7 ) raise a few questions. Llovet and colleagues ( 6 ) analyzed patients' serum VEGF levels from the SHARP trial and found that the levels could not predict response to sorafenib. This fi nding evokes the question of why VEGFA genomic amplifi cation is correlated with response to sorafenib but not VEGF serum level. Further investigation is required to address this issue. Nevertheless, this may also be true for other biomarkers for which the serum level cannot predict response but genomic amplifi cation can. Another issue about Horwitz and colleagues' ( 7 ) fi ndings is the clinical practicality. Advanced HCC is usually diagnosed with CT and MRI but not biopsy ( 9 ) , which makes using VEGFA genomic amplifi cation as a biomarker not practicable in the clinic. One possible solution is to isolate circulating tumor cells and sequence their genome to check whether there is VEGFA amplifi cation. However, taking into consideration the heterogeneity of the tumors and the relatively small number of circulating tumor cells in blood, many technical problems need to be tackled before clinical use.
The fi rst high-throughput DNA sequencing analyzer MiSeqDx system from Illumina was approved by the FDA last year. This breakthrough technology enables physicians to comprehensively obtain a patient's genetic data much more easily and quickly than before. With this information, combined with research data, doctors will be able to predict a patient's response to a specifi c treatment more accurately, which will fi nally help to realize personalized medicine. As suggested by the study by Horwitz and colleagues ( 7 ) , patients with HCC bearing VEGFA genomic amplifi cation may benefi t more from sorafenib, but patients without VEGFA genomic amplifi cation may only suffer from severe pain caused by side effects. A comprehensive genomic analysis can identify whether VEGFA is amplifi ed in a patient's HCC tumor, providing information for the doctor's decision regarding use of sorafenib.
At the end of 2013, sorafenib was approved by the FDA for advanced thyroid cancer, in addition to kidney cancer in 2005 and HCC in 2007. The NCI website shows that clinical trials of sorafenib for other cancers, including lung cancer, melanoma, and prostate cancer, are on the way. One can expect that the list of cancers that sorafenib can target will be extended in the future. However, considering the pain caused by its side effects and the economic burden of its cost, the selection of patients who are suitable for sorafenib therapy is becoming an even bigger challenge. Taken together, the identifi cation of specifi c biomarkers that predict response to sorafenib treatment for advanced-stage cancers, as done by Horwitz and colleagues ( 7 ) in this study, is worthy of more resources and efforts. Finally, the surprising anti-oncogenic roles of pro-oncogenic molecules recently identifi ed in animal HCC models call for the design of therapeutic strategies for patients with HCC by targeting secondary pathways activated in response to blockade of the primary oncogenic events ( 10 ) .
